🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. FCD105

    VYNE Therapeutics

    Acne Vulgaris

    phase 2 other completed

    1 trial

  2. FCN-437c+Fulvestrant

    The First People's Hospital of Lianyungang

    Breast Neoplasms

    phase 2 small molecule active

    1 trial

  3. FDX104 (4% Doxycycline)

    VYNE Therapeutics

    Rash Due to Epidermal Growth Factor Receptor Inhibitors

    phase 2 small molecule completed

    1 trial

  4. FGF-2

    United Therapeutics Europe Ltd

    Tympanic Membrane Perforation

    phase 2 small molecule completed

    1 trial

  5. FHD-286

    Foghorn Therapeutics

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  6. FLUDARABINE PHOSPHATE, ALDESLEUKIN, LN-145, FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE

    Iovance Biotherapeutics B.V.

    Recurrent, metastatic, or persistent Cervical Carcinoma

    phase 2 small molecule active

    1 trial

  7. FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE, TOCILIZUMAB, YTB323

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus., Lupus Nephritis

    phase 2 small molecule active

    1 trial

  8. FLUOROURACIL, JZP598, PEMBROLIZUMAB, FOLIC ACID, OXALIPLATIN

    The George Institute

    Gastroesophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  9. FMP2.1/AS01B

    United Therapeutics Europe Ltd

    Plasmodium Falciparum Malaria

    phase 2 mab completed

    1 trial

  10. FMX-103 1.5%

    VYNE Therapeutics

    Rosacea

    phase 2 small molecule completed

    1 trial

  11. FMX114

    VYNE Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  12. FOLFIRNINOX

    ACTUATE THERAPEUTICS, INC.

    Pancreatic Adenocarcinoma

    phase 2 small molecule active

    1 trial

  13. FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, S241656 film-coated tablet 50mg, Erbitux 5 mg/mL solution for infusion, Vectibix 20 mg/ml concentrate for solution for infusion, S241656 film-coated tablet 25mg, Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bugvi 5 mg/ml pulbere pentru dispersie perfuzabilă, Irinotecan Kabi 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung,

    The George Institute

    Malignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mutations

    phase 2 small molecule active

    1 trial

  14. FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, Vectibix 20 mg/ml concentrate for solution for infusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Fluorouracil Accord 50 mg/ml Injektions-/ Infusionslösung, Fluorouracile AHCL 50 mg/ml, Soluzione per iniezione o infusione, SOTORASIB, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, FLUOROURACILE ACCORD 50 mg/ml, solutio

    CERO THERAPEUTICS HOLDINGS, INC.

    colorectal cancer

    phase 2 small molecule active

    1 trial

  15. FP01

    Avalo Therapeutics

    Acute Cough

    phase 2 small molecule completed

    1 trial

  16. FP01

    Avalo Therapeutics

    Chronic Refractory Cough

    phase 2 small molecule completed

    1 trial

  17. FRUZAQLA 5 mg hard capsules, FLUOROURACIL, FOLINIC ACID, FLUOROURACIL, IRINOTECAN, OXALIPLATIN, Avastin 25 mg/ml concentrate for solution for infusion., FRUZAQLA 1 mg hard capsules

    CERO THERAPEUTICS HOLDINGS, INC.

    métastatique colorectal cancer

    phase 2 small molecule active

    1 trial

  18. FRUZAQLA 5 mg hard capsules, Tevimbra 100 mg concentrate for solution for infusion, FRUZAQLA 1 mg hard capsules, Lonsurf 15 mg/6.14 mg film-coated tablets, Avastin 25 mg/ml concentrate for solution for infusion.

    The George Institute

    Metastatic Colorectal Cancer without liver metastases

    phase 2 small molecule active

    1 trial

  19. FRα peptide plus Adjuvant (GM-CSF)

    Marker Therapeutics

    Platinum Sensitive Ovarian Cancer

    phase 2 mab terminated

    1 trial

  20. FULVESTRANT, M1774 50mg, M1774 30mg

    The George Institute

    advanced breast cancer

    phase 2 small molecule active

    1 trial

  21. FX006

    Pacira Ireland Limited

    Osteoarthritis of the Shoulder

    phase 2 small molecule terminated

    1 trial

  22. FX006 10 mg

    Pacira Ireland Limited

    Osteoarthritis of the Knee

    phase 2 small molecule completed

    2 trials

  23. FX006 32 mg

    Pacira Ireland Limited

    Osteoarthritis of the Shoulder

    phase 2 small molecule completed

    1 trial

  24. FX006 32 mg

    Pacira Ireland Limited

    Post-traumatic Osteoarthritis of the Knee

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources